Skip to main content
Premium Trial:

Request an Annual Quote

Devyser Gains CE Mark for NGS Hereditary Breast and Ovarian Cancer Test

NEW YORK – Swedish genetic test developer Devyser announced Wednesday it has received CE marking for its next-generation sequencing-based hereditary breast and ovarian cancer assay.

The targeted sequencing test analyzes 12 genes and uses a proprietary amplification-based library preparation.

"Devyser now offers a game-changing solution for hereditary breast and ovarian cancer diagnostics that enables laboratories to deliver results in just 24 hours, faster than any other product on the market," Devyser CEO and Cofounder Ulf Klangby said in a statement. "With hands-on time kept to a minimum, the lab can process large volumes quickly and deliver the critical results without any further delays." He added that the kit could help clinics work through a backlog of diagnostic testing created by the COVID-19 pandemic.

Devyser also offers a CE-marked BRCA1 and BRCA2 test kit, which can be paired with the 12 gene hereditary cancer panel.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.